Heart failure & cardiomyopathiesCase-control study
Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction
- Case-control study with experimental murine model
- replication cohort
- ultradeep error-corrected sequencing
Authors' conclusion
CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.
Study context
- Population
- Patients with HF with preserved ejection fraction (HFpEF) and controls without HFpEF; replication cohort with HFpEF; mouse model of HFpEFreplication cohort n = 59
- Participants
- 81 vs 36
- Comparison
- HFpEF vs controls without HFpEF; Clonal hematopoiesis (CH) vs no CH
- HFpEFn = 81
- Controlsn = 36reference
Main finding
As reported in the abstract
TET2-mediated CH
P = 0.02
Observational data: associations, not effects.
Further findings
| Outcome | Values | HR | P value |
|---|---|---|---|
| Diastolic dysfunction in HFpEF, CH vs no CH — CH vs No CH · E/e' | CH E/e' 14.9 · E/A 1.69 · No CH E/e' 11.7 · E/A 0.89 | P = 0.0096 | |
| Diastolic dysfunction in HFpEF, CH vs no CH — CH vs No CH · E/A | P = 0.0206 | ||
| CV-related hospitalization, HFpEF age ≥70 years, CH vs no CH | 5.06 | P = 0.042 |
Diastolic dysfunction in HFpEF, CH vs no CH
- Association of CH with exacerbated diastolic dysfunction corroborated in validation cohort
Murine HFpEF model (high-fat diet/L-NAME): Tet2-deficient vs Tet2-wild-type bone marrow
- Tet2-CH exacerbated cardiac hypertrophy, diastolic dysfunction (E/e', LV end-diastolic pressure) and cardiac fibrosis
Original publication
Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction. Circulation. Published 8 September 2023. doi:10.1161/circulationaha.123.064170
Summarised from the published abstract; every number is checked against it